Peter Clark to Mutation
This is a "connection" page, showing publications Peter Clark has written about Mutation.
Connection Strength
0.666
-
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
Score: 0.480
-
Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R. ß-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol. 2011 Dec; 179(6):3045-55.
Score: 0.082
-
Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem. 2007 Sep 21; 282(38):28189-94.
Score: 0.062
-
Lovvorn HN, Pierce J, Libes J, Li B, Wei Q, Correa H, Gouffon J, Clark PE, Axt JR, Hansen E, Newton M, O'Neill JA. Genetic and chromosomal alterations in Kenyan Wilms Tumor. Genes Chromosomes Cancer. 2015 Nov; 54(11):702-15.
Score: 0.027
-
Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clin Adv Hematol Oncol. 2007 Jul; 5(7):555-6; discussion 556-7.
Score: 0.015